2023 Year in Review

Over the 12 months of 2023, the SITC family dedicated energy and expertise to a set of incredibly strategic and impactful initiatives in support of our mission: to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation, diversity and inclusion and leadership in the field.

Read full letter >

Leisha A. Emens, MD, PhD, SITC President

Diversity, Equity & Inclusion

Diversity, equity, and inclusion (DEI) aren’t just single initiatives or individual programs for SITC: they are a core value, integrated into everything the society does and led by a passionate committee of dedicated volunteers.

Learn More

Numbers at a Glance

Total Members: 4592
  • 1,205 Net New
  • 340 20 year
  • 78 10 year
  • 23 5 year
Total Volunteers: 2484
  • 373 Committee members
  • 26 Committees
  • 2 Task Forces
International Members: 885
  • 73 Countries Represented at SITC
  • 79 LMIE Eligible Countries

Strategic Goals

Education and Scientific Exchange

Serve as the leading resource for information and education on cancer immunotherapy.

Add link to resource here

Professional Standards

Set industry standards for the field of cancer immunotherapy.

Add link to resource here

Global Access and Impact

Advance the science and application of, and equitable access to, cancer immunotherapy worldwide to eliminate disparities and improve outcomes.

Add link to resource here

Policy and Advocacy

Inform and influence the research, regulation, quality of patient care and equity of patient access impacted by public policy.

Add link to resource here

Science and Research

Challenge the thinking, seek and advance the best research to improve outcomes and develop tumor immunology and cancer immunotherapy.

Add link to resource here

Leadership Development

Cultivate the next generation of diverse leaders and innovators in tumor immunology and cancer immunotherapy.

Add link to resource here

Forward Fund

The SITC Forward Fund enables SITC to further the society’s mission and expand the knowledge of and interest in cancer immunotherapy. With the investment from the Forward Fund, SITC has awarded more than $6 million in research funding to early career investigators in the last decade. In 2023 alone, SITC supported over 90 awards for early career scientists.

Image card link goes here*

Honors and Recognition

Each year, SITC celebrates legends in the field who have contributed immeasurably to advancing the science and application of immunotherapy. These individuals serve as a source of inspiration to the next generation and a represent decades of progress for cancer patients everywhere.

Image card link goes here*